Rocket Pharmaceuticals (RCKT) Depreciation and Depletion (2015 - 2023)

Rocket Pharmaceuticals has disclosed Depreciation and Depletion across 9 years of filings, most recently posting $1.2 million for Q3 2023.

• Depreciation and Depletion for Q3 2023 came in at $1.2 million, up 9.09% year-over-year; the trailing twelve-month figure through Sep 2023 was $1.5 million (down 60.4% YoY), and the FY2022 annual result was $800000.0, changed N/A from the prior year.
• Depreciation and Depletion came in at $1.2 million for Q3 2023 at Rocket Pharmaceuticals, roughly flat from $1.2 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $1.2 million in Q2 2023 to a low of -$2.1 million in Q4 2022.
• The 5-year median for Depreciation and Depletion is $442500.0 (2020), against an average of $410000.0.
• Across the five-year window, Depreciation and Depletion changed 0.0% in 2019 and surged 47.98% in 2023, its largest moves.
• Rocket Pharmaceuticals' Depreciation and Depletion stood at $101000.0 in 2019, then dropped by 0.99% to $100000.0 in 2020, then surged by 700.0% to $800000.0 in 2021, then tumbled by 360.38% to -$2.1 million in 2022, then surged by 157.61% to $1.2 million in 2023.
• The last three Depreciation and Depletion figures came in at $1.2 million (Q3 2023), $1.2 million (Q2 2023), and $1.1 million (Q1 2023), per Business Quant data.